Dr. Yael Cohen on VB111 as a Potential Treatment for Ovarian Cancer

December 28, 2015
Yael Cohen, MD

Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.

Yael Cohen, MD, vice president, Clinical Development, VBL Therapeutics, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.

Cohen says the treatment was initially tested in ovarian cancer as a dose escalation phase I trial across 3 cohorts of patients. She said in the phase I trial, researchers saw an overall response rate of about 60% in participating patients with platinum-resistant ovarian cancer.